Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Ying Sheng, Chiung-Yu Huang, PhD, Sophia Byslma, BS, Kelsey Natsuhara, MD, Dhruba Biswas, Mimi Lo, PharmD, BCPS, BCOP, Weiyun Z. Ai, Lawrence D Kaplan, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Charalambos Andreadis, MD MSCE, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138940

Published: 2020

Journal Articles

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Juan Carlos Ramos, MD BS, Richard F. Ambinder, MD, Joseph Sparano, MD, Jeannette Y Lee, PhD, Lawrence D Kaplan, MD, William Wachsman, MD PhD, David M. Aboulafia, MD, Ariela Noy, MD, Lee Ratner, MD PhD, David H. Henry, MD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Ronald T. Mitsuyasu, MD

Blood (2019) 134 (Supplement_1): 2872.

https://doi.org/10.1182/blood-2019-123558

Published: 2019

Journal Articles

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Weiyun Ai, MD PhD, Lawrence D Kaplan, MD, Joseph Tuscano, MD, Matthew J. Wieduwilt, MD PhD, Akshay Sudhindra, MD, Jimmy Hwang, PhD, Jesika Reiner, MPH, Michelle Martinelli, Charlie Aoun, BS, Teresa Ta, Diem Le, Michelle Padilla, Erika Crawford, Charalambos Andreadis, MD

Blood (2019) 134 (Supplement_1): 2828.

https://doi.org/10.1182/blood-2019-123279

Published: 2019

Journal Articles

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Blood (2019) 134 (Supplement_1): 4525.

https://doi.org/10.1182/blood-2019-129488

Published: 2019

Journal Articles

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Juan Carlos Ramos, MD BS, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y Lee, PhD, Erin G. Reid, MD MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD PhD, Lee Ratner, MD PhD, Robert A Baiocchi, MD PhD, David M. Aboulafia, MD, Lawrence D Kaplan, MD, Adam Capoferri, Ronald T. Mitsuyasu, MD, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1588.

https://doi.org/10.1182/blood-2019-129687

Published: 2019

Journal Articles

Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

Matthew J Maurer, MS, Amy S. Ruppert, MAS, PhD, Brian K. Link, MD, Lawrence D Kaplan, MD, David J Inwards, MD, Andrew L. Feldman, MD, Eric D. Hsi, MD, Adam Pettinger, Jonathon B. Cohen, MD MS, Peter Martin, FRCPC, MD MS, Brad S Kahl, MD, Nancy L. Bartlett, MD, James R. Cerhan, MD PhD, John P. Leonard, MD, Thomas M. Habermann, MD

Blood (2018) 132 (Supplement 1): 2878.

https://doi.org/10.1182/blood-2018-99-110558

Published: 2018

Journal Articles

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Lawrence D Kaplan, MD, Matthew J. Maurer, MS, Wendy Stock, MD, Nancy L. Bartlett, MD, Noreen Fulton, BS, Adam Pettinger, John C. Byrd, MD, Kristie A. Blum, MD, Ann S. LaCasce, MD MSc, David Duane Hurd, MD, Amy S. Ruppert, MAS, PhD, Francisco J. Hernandez-Ilizaliturri, MD, John P. Leonard, MD, Bruce Cheson, MD

Blood (2018) 132 (Supplement 1): 146.

https://doi.org/10.1182/blood-2018-99-112655

Published: 2018

Journal Articles

High Prevalence and Incidence of Fractures in Patients Treated for Aggressive B-Cell Non-Hodgkin Lymphomas

Li-Wen Huang, MD, Dong Sun, MD PhD, Weiyun Ai, MD PhD, Lawrence D Kaplan, MD, Thomas M Link, MD PhD, Thomas Lang, PhD, Charalambos Andreadis, MD MSCE

Blood (2017) 130 (Supplement 1): 4131.

https://doi.org/10.1182/blood.V130.Suppl_1.4131.4131

Published: 2017

Journal Articles

Cell of Origin and Double Protein Expression As Predictors of Outcome after Autologous Stem Cell Transplant for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Undergo Intensive Consolidation Therapy (ICT) and Autologous Stem Cell Transplant (AutoSCT)

Bradley Hunter, MD MPH, Ben Rosen, MD, Miguel Castillo, Lawrence D. Kaplan, MD, Weiyun Z. Ai, MD PhD, Lloyd E. Damon, MD, Thomas G. Martin, III, MD, Charalambos Andreadis, MD MSCE

Blood (2016) 128 (22): 4638.

https://doi.org/10.1182/blood.V128.22.4638.4638

Published: 2016

Journal Articles

Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

Blood (2016) 128 (22): 1346.

https://doi.org/10.1182/blood.V128.22.1346.1346

Published: 2016

Journal Articles

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Lawrence D. Kaplan, MD, Sin-Ho Jung, PhD, Wendy Stock, MD, Nancy L. Bartlett, MD, Brandelyn Pitcher, MS, John C. Byrd, MD, Kristie A. Blum, MD, Ann S. LaCasce, MD, Noreen Fulton, Eric D. Hsi, MD, David D Hurd, MD, Myron Czuczman, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 337.

https://doi.org/10.1182/blood.V126.23.337.337

Published: 2015

Journal Articles

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Noreen Fulton, B.S., Jeffrey Johnson, M.S., Lawrence D. Kaplan, M.D., Greg Koval, B.S., Greg Malnassy, B.S., Sin-Ho Jung, Ph.D., Steve Devine, M.D., Thomas C. Shea, M.D., John P. Leonard, M.D., Bruce D. Cheson, M.D., Wendy Stock, M.D.

Blood (2013) 122 (21): 3002.

https://doi.org/10.1182/blood.V122.21.3002.3002

Published: 2013

Journal Articles

Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia

Gabriel N. Mannis, MD, Lloyd E Damon, MD, Weiyun Z. Ai, MD, PhD, Charalambos Andreadis, MD, MS, Karin ML Gaensler, MD, Neel K. Gupta, M.D., Lawrence D. Kaplan, M.D., Andrew D. Leavitt, MD, Aaron C. Logan, MD, PhD, Rebecca L. Olin, MD, MS, Peter H. Sayre, MD, PhD, Catherine C Smith, MD, Jeffrey M Venstrom, MD, Thomas G Martin, III, MD

Blood (2013) 122 (21): 2172.

https://doi.org/10.1182/blood.V122.21.2172.2172

Published: 2013

Journal Articles

Vincristine Sulfate Liposome Injection (Marqibo ® ) and Rituximab For Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma Or Mantle Cell Lymphoma In Need Of Palliative Therapy

Lawrence D. Kaplan, MD, Steven R. Deitcher, MD, Jeffrey A. Silverman, Ph.D., Gareth J Morgan, MD, PhD

Blood (2013) 122 (21): 4355.

https://doi.org/10.1182/blood.V122.21.4355.4355

Published: 2013

Journal Articles

Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)

Greg Malnassy, MS, Susan Geyer, PhD, Noreen Fulton, B.S., Greg Koval, B.S., Donna Niedzwiecki, PhD, Victoria Carlton, PhD, Li Weng, PhD, Lawrence D. Kaplan, MD, Guido Marcucci, MD, Lloyd E Damon, MD, Richard A. Larson, MD, Richard M. Stone, MD, Bruce D. Cheson, M.D., Malek Faham, MD, PhD, Wendy Stock, M.D.

Blood (2013) 122 (21): 2547.

https://doi.org/10.1182/blood.V122.21.2547.2547

Published: 2013

Journal Articles

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

Blood (2013) 122 (19): 3251–3262.

https://doi.org/10.1182/blood-2013-04-498964

Published: 2013

Includes: Supplemental data

Journal Articles

CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma

James L. Rubenstein, Valerie S. Wong, Cigall Kadoch, Hua-Xin Gao, Ramon Barajas, Lingjing Chen, S. Andrew Josephson, Brian Scott, Vanja Douglas, Mekhala Maiti, Lawrence D. Kaplan, Patrick A. Treseler, Soonmee Cha, Jimmy H. Hwang, Paola Cinque, Jason G. Cyster, Clifford Lowell

Blood (2013) 121 (23): 4740–4748.

https://doi.org/10.1182/blood-2013-01-476333

Published: 2013

Includes: Supplemental data

Journal Articles

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

James L. Rubenstein, M.D., Ph.D., Eric D. Hsi, MD, Jeffrey L. Johnson, Sin-Ho Jung, Barbara Grant, MD, Bruce D. Cheson, MD, Lawrence D. Kaplan, MD

Blood (2012) 120 (21): 301.

https://doi.org/10.1182/blood.V120.21.301.301

Published: 2012

Journal Articles

ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era

Stefan K Barta, MD, MS, MRCP, Xiaonan Xue, Ph.D., Dan Wang, MS, Jeannette Y Lee, Ph.D., Lawrence D. Kaplan, MD, Josep-Maria Ribera, MD, PhD, Albert Oriol, Olga Garcia, Mireia Morgades, Michele Spina, MD, Umberto Tirelli, MD, Francois Boue, MD, PhD, Wyndham H. Wilson, MD, PhD, Christoph Wyen, MD, Kieron Dunleavy, MD, Joseph A Sparano, MD

Blood (2012) 120 (21): 1564.

https://doi.org/10.1182/blood.V120.21.1564.1564

Published: 2012

Journal Articles

A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes

Blood (2012) 120 (21): 3682.

https://doi.org/10.1182/blood.V120.21.3682.3682

Published: 2012

NARROW

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

High Prevalence and Incidence of Fractures in Patients Treated for Aggressive B-Cell Non-Hodgkin Lymphomas

Cell of Origin and Double Protein Expression As Predictors of Outcome after Autologous Stem Cell Transplant for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Undergo Intensive Consolidation Therapy (ICT) and Autologous Stem Cell Transplant (AutoSCT)

Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia

Vincristine Sulfate Liposome Injection (Marqibo ® ) and Rituximab For Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma Or Mantle Cell Lymphoma In Need Of Palliative Therapy

Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era

A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only